OR24-02 Case Series Of Canadian Patients With Homozygous Familial Hypercholesterolemia Treated With ANGPTL3 Inhibitor Evinacumab

Disclosure: I. Shamsudeen: None. B.W. McCrindle: Consulting Fee; Self; Jansen Pharmaceuticals, Amryt, Ultragenyx, Chiesi, Esperion. R.A. Hegele: Advisory Board Member; Self; Amgen Inc, HLS Pharmaceuticals, Novartis Pharmaceuticals. Consulting Fee; Self; Akcea Therapeutics, Ultragenyx, Medison, Acast...

Descripción completa

Detalles Bibliográficos
Autores principales: Shamsudeen, Isabel, McCrindle, Brian W, Hegele, Robert A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Cardiovascular Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554401/
http://dx.doi.org/10.1210/jendso/bvad114.673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554401/
http://dx.doi.org/10.1210/jendso/bvad114.673

Ejemplares similares